The combination of strong top-line growth, expanding profitability, rising backlog, and new FDA clearances suggests accelerating commercial momentum. Traders should monitor execution against the aggressive 2026 EBITDA guidance and adoption of the new adolescent and SWIFT protocols as key catalysts.
Price Chart
Executive Summary
BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY revenue growth to $52.2 million, net income up 161% to $7.6 million, and raised 2026 guidance projecting $66–68 million in revenue (27–30% growth) and Adjusted EBITDA of $12–14 million (86–100% growth). The company also secured FDA clearances for adolescent depression and an accelerated treatment protocol, expanding its market potential.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $14.5M (+27% YoY)
- Full-year 2025 revenue: $52.2M (+27% YoY)
- Full-year 2025 net income: $7.6M (+161% YoY)
- Adjusted EBITDA for 2025: $7.0M (+55% YoY)
- Remaining performance obligations up 43% to $70M
- 2026 revenue guidance: $66M–$68M (27–30% growth)
- 2026 Adjusted EBITDA guidance: $12M–$14M (86–100% growth)
- FDA cleared Deep TMS for adolescents (15–21) with MDD and approved accelerated SWIFT™ protocol
Financial Impact
Revenue growth accelerating at scale with expanding margins; $18M midpoint increase in Adjusted EBITDA expected in 2026
Risk Factors
- Forward-looking guidance may not be achieved
- High growth expectations already priced into stock (OTC market, $961M market cap)
- Cash balance declined slightly despite strong net income due to working capital outflows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253665 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access